Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (£272m) over five years over Washington's demand for confidential biological samples.
This rejection was revealed following a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesman has since clarified that the US was seeking health data for research and profit but was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more negotiations to reach a deal suitable to both sides so the nation's critical HIV programme can continue.
Wider Implications
This development follows a comparable situation in neighbouring Kenya, where a high court blocked a similar deal with the US after legal challenges were filed about the safety of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral agreements to enhance transparency and responsibility.
According to statements, Sixteen nations in Africa have to date agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, without any corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"In essence, our country would provide the raw materials for medical research with no certainty that the final treatments would be accessible to our people should a future disease outbreak emerge."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its pursuit of one-on-one health agreements were upending systems previously set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is intended to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage further dialogue with our American counterparts on how future co-operation could be structured in a manner that honours the independence and interests of both nations."
Medical Community Response
Medical experts expressed it understood the official position, but suggested that talks should continue considering a large portion of the country's Aids initiatives depended on foreign aid.
"In cases where technical issues exist, such as those relating to information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it added.
The halted deal highlights the continuing challenges between accepting vital foreign assistance and protecting local interests in an ever more interconnected world.